$1.7M
3.3x
Subscribe Free
Read the full deal writeup
Sign up for a free Accredited account to read the editorial writeup, financials, and broker contact for this deal.
Get Free AccessFull Editorial Writeup
Very high-volume specialty pharmacy that has been in business for four years with continued growth. All major PBM contracts in place through PSAO. Fully staffed and easily operated by an absentee owner. Direct contracts with many pharma manufactures. Established Prior-Authorization P&P. Pharma voucher...
Why we like it
- Cash flow margin profile suggests pricing power in specialty pharmaceutical dispensing, where complex medications and specialized services command higher reimbursement rates than traditional pharmacy retail. The 3.3x multiple on $1.7M cash flow indicates either strong growth trajectory or the seller's urgency, both creating acquisition opportunity.
- PBM contract coverage through PSAO provides durable revenue moat since patients can't easily switch pharmacies once established in specialty care protocols. Prior authorization expertise and manufacturer relationships create switching costs that protect customer retention in a healthcare vertical with natural stickiness.
- Specialty pharmacy market continues expanding as pharmaceutical innovation drives more complex, high-value treatments requiring specialized dispensing and patient management services. Aging demographics and increased prevalence of chronic conditions requiring specialty medications provide structural tailwinds.
- Absentee operation model suggests systematized processes that reduce key person risk while maintaining operational efficiency in a typically hands-on healthcare business. Four years of operation with continued growth indicates the business has moved beyond startup phase into scalable systems.
How to improve it
- Audit all PBM reimbursement rates and negotiate direct contracts where PSAO arrangements may be leaving margin on the table, particularly for high-volume medication categories. Review contract terms for automatic renewals and rate escalation clauses that could improve long-term economics.
- Implement comprehensive patient adherence and outcome tracking systems to demonstrate value to PBMs and manufacturers, positioning for value-based care contracts that typically offer higher margins than traditional fee-for-service dispensing arrangements.
- Expand direct manufacturer relationships beyond current portfolio to capture rebates, patient assistance program administration fees, and co-pay offset programs that can significantly improve per-prescription economics without additional operational complexity.
- Develop clinical services offerings like medication therapy management, injection administration, or specialized compounding services that command premium reimbursement rates while deepening patient relationships and creating additional revenue streams.
- Systematize new patient acquisition through physician detailing and referral programs, focusing on high-value specialty medication categories where the pharmacy can demonstrate superior clinical outcomes and patient satisfaction compared to mail-order competitors.
- Optimize inventory management through demand forecasting and supplier relationship improvements to reduce carrying costs for high-value specialty medications while ensuring availability for critical patient needs.
- Explore geographic expansion opportunities within Ohio or adjacent states using the proven operational model, particularly in underserved markets where specialty pharmacy access remains limited.
- Implement advanced pharmacy management software with integrated clinical decision support and automated prior authorization processing to improve operational efficiency while reducing staffing requirements as volume scales.
Diligence notes
- Verify the sustainability of current PBM relationships and understand any pending contract renewals or rate changes, as reimbursement rate cuts could significantly impact cash flow in pharmacy operations. Request detailed breakdown of revenue by PBM to assess concentration risk.
- Review state pharmacy licensing requirements and any pending regulatory changes in Ohio that could impact specialty pharmacy operations, including controlled substance handling protocols and clinical service scope of practice limitations that might affect expansion plans.
- Analyze patient concentration risk by reviewing the top medication categories and patient counts to ensure the business isn't overly dependent on a small number of high-value patients whose treatment changes could impact revenue significantly.
- Examine the financial relationship with pharmaceutical manufacturers including rebate agreements, patient assistance program administration, and any minimum volume commitments that could create future operational or financial obligations for the buyer.